Huakang Biomedical Holdings Company Limited
Huakang Biomedical Holdings Company Limited (8622.HK) Stock Competitors & Peer Comparison
See (8622.HK) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 8622.HK | HK$0.33 | +1.56% | 170.1M | -33.00 | -HK$0.01 | N/A |
| 3692.HK | HK$38.38 | -2.49% | 234B | 36.07 | HK$1.07 | +0.95% |
| 2196.HK | HK$20.08 | -0.30% | 73.8B | 13.50 | HK$1.46 | +1.78% |
| 0874.HK | HK$16.97 | +1.01% | 41B | 7.83 | HK$2.11 | +5.30% |
| 3320.HK | HK$5.24 | -9.34% | 33.2B | 7.25 | HK$0.73 | +2.55% |
| 0867.HK | HK$13.19 | -1.35% | 31.9B | 18.39 | HK$0.71 | +2.50% |
| 1513.HK | HK$28.24 | -0.35% | 30.8B | 11.10 | HK$2.54 | +4.25% |
| 0512.HK | HK$6.37 | -2.90% | 22.2B | 10.75 | HK$0.59 | N/A |
| 3933.HK | HK$9.54 | -3.15% | 18.8B | 7.51 | HK$1.27 | +5.97% |
| 0013.HK | HK$21.32 | -2.56% | 18.3B | 5.13 | HK$4.15 | N/A |
Stock Comparison
8622.HK vs 3692.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 3692.HK has a market cap of 234B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 3692.HK trades at HK$38.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 3692.HK's P/E ratio is 36.07. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 3692.HK's ROE of +0.17%. Regarding short-term risk, 8622.HK is less volatile compared to 3692.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 3692.HK's competition here
8622.HK vs 2196.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 2196.HK has a market cap of 73.8B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 2196.HK trades at HK$20.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 2196.HK's P/E ratio is 13.50. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 2196.HK's ROE of +0.09%. Regarding short-term risk, 8622.HK is less volatile compared to 2196.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 2196.HK's competition here
8622.HK vs 0874.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 0874.HK has a market cap of 41B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 0874.HK trades at HK$16.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 0874.HK's P/E ratio is 7.83. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 0874.HK's ROE of +0.08%. Regarding short-term risk, 8622.HK is less volatile compared to 0874.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 0874.HK's competition here
8622.HK vs 3320.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 3320.HK has a market cap of 33.2B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 3320.HK trades at HK$5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 3320.HK's P/E ratio is 7.25. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 3320.HK's ROE of +0.08%. Regarding short-term risk, 8622.HK is less volatile compared to 3320.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 3320.HK's competition here
8622.HK vs 0867.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 0867.HK has a market cap of 31.9B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 0867.HK trades at HK$13.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 0867.HK's P/E ratio is 18.39. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 0867.HK's ROE of +0.09%. Regarding short-term risk, 8622.HK is less volatile compared to 0867.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 0867.HK's competition here
8622.HK vs 1513.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 1513.HK has a market cap of 30.8B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 1513.HK trades at HK$28.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 1513.HK's P/E ratio is 11.10. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 1513.HK's ROE of +0.14%. Regarding short-term risk, 8622.HK is less volatile compared to 1513.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 1513.HK's competition here
8622.HK vs 0512.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 0512.HK has a market cap of 22.2B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 0512.HK trades at HK$6.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 0512.HK's P/E ratio is 10.75. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 0512.HK's ROE of +0.07%. Regarding short-term risk, 8622.HK is less volatile compared to 0512.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 0512.HK's competition here
8622.HK vs 3933.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 3933.HK has a market cap of 18.8B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 3933.HK trades at HK$9.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 3933.HK's P/E ratio is 7.51. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 3933.HK's ROE of +0.13%. Regarding short-term risk, 8622.HK is less volatile compared to 3933.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 3933.HK's competition here
8622.HK vs 0013.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 0013.HK has a market cap of 18.3B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 0013.HK trades at HK$21.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 0013.HK's P/E ratio is 5.13. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 0013.HK's ROE of +0.41%. Regarding short-term risk, 8622.HK is less volatile compared to 0013.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 0013.HK's competition here
8622.HK vs 9989.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 9989.HK has a market cap of 16.3B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 9989.HK trades at HK$4.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 9989.HK's P/E ratio is 17.93. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 9989.HK's ROE of +0.03%. Regarding short-term risk, 8622.HK is more volatile compared to 9989.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 8622.HK.Check 9989.HK's competition here
8622.HK vs 1558.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 1558.HK has a market cap of 14B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 1558.HK trades at HK$15.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 1558.HK's P/E ratio is 26.47. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 1558.HK's ROE of +0.06%. Regarding short-term risk, 8622.HK is less volatile compared to 1558.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 1558.HK's competition here
8622.HK vs 1681.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 1681.HK has a market cap of 13.2B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 1681.HK trades at HK$15.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 1681.HK's P/E ratio is 10.85. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 1681.HK's ROE of +0.24%. Regarding short-term risk, 8622.HK is less volatile compared to 1681.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 1681.HK's competition here
8622.HK vs 2575.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 2575.HK has a market cap of 12.6B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 2575.HK trades at HK$25.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 2575.HK's P/E ratio is -39.84. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 2575.HK's ROE of -0.54%. Regarding short-term risk, 8622.HK is less volatile compared to 2575.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 2575.HK's competition here
8622.HK vs 0460.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 0460.HK has a market cap of 12.1B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 0460.HK trades at HK$1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 0460.HK's P/E ratio is 66.00. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 0460.HK's ROE of +0.03%. Regarding short-term risk, 8622.HK is less volatile compared to 0460.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 0460.HK's competition here
8622.HK vs 6185.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 6185.HK has a market cap of 11.3B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 6185.HK trades at HK$32.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 6185.HK's P/E ratio is -41.95. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 6185.HK's ROE of +0.01%. Regarding short-term risk, 8622.HK is less volatile compared to 6185.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 6185.HK's competition here
8622.HK vs 2627.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 2627.HK has a market cap of 10.6B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 2627.HK trades at HK$29.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 2627.HK's P/E ratio is -45.11. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 2627.HK's ROE of -1.43%. Regarding short-term risk, 8622.HK is less volatile compared to 2627.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 2627.HK's competition here
8622.HK vs 0719.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 0719.HK has a market cap of 9.3B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 0719.HK trades at HK$6.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 0719.HK's P/E ratio is 12.85. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 0719.HK's ROE of +0.06%. Regarding short-term risk, 8622.HK is less volatile compared to 0719.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 0719.HK's competition here
8622.HK vs 0570.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 0570.HK has a market cap of 8.6B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 0570.HK trades at HK$1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 0570.HK's P/E ratio is -21.37. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 0570.HK's ROE of -0.02%. Regarding short-term risk, 8622.HK is more volatile compared to 0570.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 8622.HK.Check 0570.HK's competition here
8622.HK vs 2877.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 2877.HK has a market cap of 7.3B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 2877.HK trades at HK$9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 2877.HK's P/E ratio is 6.68. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 2877.HK's ROE of +0.12%. Regarding short-term risk, 8622.HK is less volatile compared to 2877.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 2877.HK's competition here
8622.HK vs 2005.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 2005.HK has a market cap of 7B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 2005.HK trades at HK$2.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 2005.HK's P/E ratio is 14.87. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 2005.HK's ROE of +0.06%. Regarding short-term risk, 8622.HK is less volatile compared to 2005.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 2005.HK's competition here
8622.HK vs 2552.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 2552.HK has a market cap of 3.3B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 2552.HK trades at HK$3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 2552.HK's P/E ratio is 2.63. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 2552.HK's ROE of +1.07%. Regarding short-term risk, 8622.HK is less volatile compared to 2552.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 2552.HK's competition here
8622.HK vs 2561.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 2561.HK has a market cap of 2.7B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 2561.HK trades at HK$24.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 2561.HK's P/E ratio is -8.92. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 2561.HK's ROE of -0.26%. Regarding short-term risk, 8622.HK is more volatile compared to 2561.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 8622.HK.Check 2561.HK's competition here
8622.HK vs 6896.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 6896.HK has a market cap of 2.7B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 6896.HK trades at HK$3.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 6896.HK's P/E ratio is 8.74. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 6896.HK's ROE of +0.19%. Regarding short-term risk, 8622.HK is more volatile compared to 6896.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 8622.HK.Check 6896.HK's competition here
8622.HK vs 2633.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 2633.HK has a market cap of 2.3B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 2633.HK trades at HK$1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 2633.HK's P/E ratio is 7.60. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 2633.HK's ROE of +0.13%. Regarding short-term risk, 8622.HK is less volatile compared to 2633.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 2633.HK's competition here
8622.HK vs 2161.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 2161.HK has a market cap of 2B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 2161.HK trades at HK$2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 2161.HK's P/E ratio is 8.93. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 2161.HK's ROE of +0.20%. Regarding short-term risk, 8622.HK is more volatile compared to 2161.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 8622.HK.Check 2161.HK's competition here
8622.HK vs 3839.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 3839.HK has a market cap of 1.8B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 3839.HK trades at HK$7.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 3839.HK's P/E ratio is 7.71. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 3839.HK's ROE of +0.12%. Regarding short-term risk, 8622.HK is less volatile compared to 3839.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 3839.HK's competition here
8622.HK vs 1061.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 1061.HK has a market cap of 1.8B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 1061.HK trades at HK$3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 1061.HK's P/E ratio is 5.71. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 1061.HK's ROE of +0.14%. Regarding short-term risk, 8622.HK is less volatile compared to 1061.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 1061.HK's competition here
8622.HK vs 2348.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 2348.HK has a market cap of 1.7B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 2348.HK trades at HK$1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 2348.HK's P/E ratio is 8.69. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 2348.HK's ROE of +0.06%. Regarding short-term risk, 8622.HK is less volatile compared to 2348.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 2348.HK's competition here
8622.HK vs 8049.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 8049.HK has a market cap of 1.4B. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 8049.HK trades at HK$2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 8049.HK's P/E ratio is 5.93. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 8049.HK's ROE of +0.14%. Regarding short-term risk, 8622.HK is less volatile compared to 8049.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 8049.HK's competition here
8622.HK vs 1349.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 1349.HK has a market cap of 948.6M. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 1349.HK trades at HK$2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 1349.HK's P/E ratio is -93.00. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 1349.HK's ROE of -0.07%. Regarding short-term risk, 8622.HK is more volatile compared to 1349.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 8622.HK.Check 1349.HK's competition here
8622.HK vs 1652.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 1652.HK has a market cap of 872.4M. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 1652.HK trades at HK$1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 1652.HK's P/E ratio is -59.00. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 1652.HK's ROE of -0.03%. Regarding short-term risk, 8622.HK is less volatile compared to 1652.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 1652.HK's competition here
8622.HK vs 0239.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 0239.HK has a market cap of 779.1M. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 0239.HK trades at HK$2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 0239.HK's P/E ratio is 10.87. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 0239.HK's ROE of +0.13%. Regarding short-term risk, 8622.HK is more volatile compared to 0239.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 8622.HK.Check 0239.HK's competition here
8622.HK vs 0503.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 0503.HK has a market cap of 750.6M. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 0503.HK trades at HK$1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 0503.HK's P/E ratio is 13.77. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 0503.HK's ROE of +0.07%. Regarding short-term risk, 8622.HK is less volatile compared to 0503.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 0503.HK's competition here
8622.HK vs 3737.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 3737.HK has a market cap of 675M. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 3737.HK trades at HK$0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 3737.HK's P/E ratio is 40.00. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 3737.HK's ROE of +0.02%. Regarding short-term risk, 8622.HK is more volatile compared to 3737.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 8622.HK.Check 3737.HK's competition here
8622.HK vs 0950.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 0950.HK has a market cap of 659.5M. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 0950.HK trades at HK$1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 0950.HK's P/E ratio is 7.00. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 0950.HK's ROE of +0.06%. Regarding short-term risk, 8622.HK is more volatile compared to 0950.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 8622.HK.Check 0950.HK's competition here
8622.HK vs 1011.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 1011.HK has a market cap of 426.7M. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 1011.HK trades at HK$0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 1011.HK's P/E ratio is -13.00. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 1011.HK's ROE of +0.09%. Regarding short-term risk, 8622.HK is more volatile compared to 1011.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 8622.HK.Check 1011.HK's competition here
8622.HK vs 0897.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 0897.HK has a market cap of 367.7M. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 0897.HK trades at HK$0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 0897.HK's P/E ratio is -33.00. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 0897.HK's ROE of -0.01%. Regarding short-term risk, 8622.HK is less volatile compared to 0897.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 0897.HK's competition here
8622.HK vs 8329.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 8329.HK has a market cap of 214.8M. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 8329.HK trades at HK$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 8329.HK's P/E ratio is -4.27. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 8329.HK's ROE of -0.06%. Regarding short-term risk, 8622.HK is less volatile compared to 8329.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 8329.HK's competition here
8622.HK vs 0455.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 0455.HK has a market cap of 208.6M. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 0455.HK trades at HK$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 0455.HK's P/E ratio is -3.23. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 0455.HK's ROE of -0.15%. Regarding short-term risk, 8622.HK is more volatile compared to 0455.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 8622.HK.Check 0455.HK's competition here
8622.HK vs 0858.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 0858.HK has a market cap of 174.7M. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 0858.HK trades at HK$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 0858.HK's P/E ratio is -0.49. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 0858.HK's ROE of -0.30%. Regarding short-term risk, 8622.HK is less volatile compared to 0858.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 0858.HK's competition here
8622.HK vs 0911.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 0911.HK has a market cap of 167.8M. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 0911.HK trades at HK$0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 0911.HK's P/E ratio is 24.75. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 0911.HK's ROE of +0.01%. Regarding short-term risk, 8622.HK is less volatile compared to 0911.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 0911.HK's competition here
8622.HK vs 1498.HK Comparison April 2026
8622.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 8622.HK stands at 170.1M. In comparison, 1498.HK has a market cap of 123.5M. Regarding current trading prices, 8622.HK is priced at HK$0.33, while 1498.HK trades at HK$0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
8622.HK currently has a P/E ratio of -33.00, whereas 1498.HK's P/E ratio is -3.69. In terms of profitability, 8622.HK's ROE is -0.12%, compared to 1498.HK's ROE of -0.30%. Regarding short-term risk, 8622.HK is less volatile compared to 1498.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 8622.HK.Check 1498.HK's competition here